Milano – recordati Shopping in the UK and expanding into rare disease treatment. Italian company farmaxceutica – explains a note – has signed an agreement to acquire Usa Pharma, a global specialist pharmaceutical company based in the United Kingdom, focused on specific rare and oncological diseases and managed by EW Healthcare Partners. controlled by the fund. Recordati will acquire Usa Pharma for an enterprise value of €750 million.
operation – explains the note – will provide a recordati A portfolio of pharmaceutical products for rare diseases, which is expected to contribute in 2023 with revenues of more than EUR 150 million and moles of approximately 50 million. Non-recurring costs in 2022-2023 from non-recurring costs, transfer of production technologies and expenses related to acquisition and integration are estimated to be approximately ₹35 million (figure subject to closing time of operations). Yusa’s product portfolio is expected to reach maximum annual total sales of approximately EUR 250 million, including the potential approval of Karjiba in the United States, with an EBITDA margin in line with the current average profitability of the rare disease segment. The closing of the transaction is subject to regulatory authorities and is expected to take place in the first half of 2022. Does not change the dividend policy of the transaction recordati, confirmed the payout ratio at 60% of consolidated net profit.
“We believe that the acquisition of Usa Pharma represents an excellent opportunity to further expand and strengthen our portfolio with products with high growth potential in a new and under-served therapeutic area that specializes in rare and specific oncological diseases. which also provides us with a platform for possible future expansion in these areas is: improving the lives of patients, providing innovative treatments that address serious medical needs that have not been met,” said Andrea recordati, President
Organizer. Zombie aficionado. Wannabe reader. Passionate writer. Twitter lover. Music scholar. Web expert.